医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2012年
30期
35-36
,共2页
支原体肺炎%罗红霉素%阿奇霉素%临床疗效%安全性
支原體肺炎%囉紅黴素%阿奇黴素%臨床療效%安全性
지원체폐염%라홍매소%아기매소%림상료효%안전성
Mycoplasma pneumonia%Roxithromycin%Azithromycin%Clinical efficacy%Safety
目的探讨罗红霉素与阿奇霉素治疗成人支原体肺炎临床疗效和安全性.方法将86例我院住院治疗的支原体肺炎患者分为 A 组和 B 组,每组各43例患者,A 组患者给予罗红霉素治疗,而 B 组患者则给予阿奇霉素治疗.治疗14天,比较两组患者的临床疗效和药物不良反应发生情况.结果 B 组患者治疗总有效率差异无统计学意义(P>0.05),B 组患者在恶心呕吐发生率方面明显低于 A 组患者的,差异有统计学意义(P<0.05).结论阿奇霉素治疗成人支原体肺炎临床疗效确切,与罗红霉素疗效相当,具有安全可靠和不良反应少等特点.
目的探討囉紅黴素與阿奇黴素治療成人支原體肺炎臨床療效和安全性.方法將86例我院住院治療的支原體肺炎患者分為 A 組和 B 組,每組各43例患者,A 組患者給予囉紅黴素治療,而 B 組患者則給予阿奇黴素治療.治療14天,比較兩組患者的臨床療效和藥物不良反應髮生情況.結果 B 組患者治療總有效率差異無統計學意義(P>0.05),B 組患者在噁心嘔吐髮生率方麵明顯低于 A 組患者的,差異有統計學意義(P<0.05).結論阿奇黴素治療成人支原體肺炎臨床療效確切,與囉紅黴素療效相噹,具有安全可靠和不良反應少等特點.
목적탐토라홍매소여아기매소치료성인지원체폐염림상료효화안전성.방법장86례아원주원치료적지원체폐염환자분위 A 조화 B 조,매조각43례환자,A 조환자급여라홍매소치료,이 B 조환자칙급여아기매소치료.치료14천,비교량조환자적림상료효화약물불량반응발생정황.결과 B 조환자치료총유효솔차이무통계학의의(P>0.05),B 조환자재악심구토발생솔방면명현저우 A 조환자적,차이유통계학의의(P<0.05).결론아기매소치료성인지원체폐염림상료효학절,여라홍매소료효상당,구유안전가고화불량반응소등특점.
Objective To investigate the clinical efficacy and safety of adult with mycoplasma pneumonia by roxithromycin and azithromycin.Methods 86 cases of adult with mycoplasma pneumonia who were in our hospital were colect,they were divided into group A (cases=43)and group B (cases=43)by random number table.The patients in group A were given roxithromycin,but the patients in group B were given azithromycin.Then the clinical efficacy after fourteen days ’ treatment were compared.Results After fourteen days’ treatment,the total efficiency rate of of the two groups were no different(P>0.05),the adverse reaction rate of group B were significantly lower than that in group A’(P<0.05).Conclusion The clinical efficacy of roxithromycin or azithromycin is sure for adult with mycoplasma pneumonia.It is low recurrence and adverse reaction rate.
